4:08 PM
 | 
Mar 07, 2018
 |  BC Extra  |  Clinical News

Esperion reports first Phase III hypercholesterolemia data

Esperion Therapeutics Inc. (NASDAQ:ESPR) said once-daily oral bempedoic acid (ETC-1002) met the primary endpoint in the Phase III CLEAR Tranquility (1002-048) trial to treat hypercholesterolemia in patients with atherosclerotic cardiovascular disease (ASCVD). The company also reported that two patients in the bempedoic acid arm had liver enzyme elevations that were more than three times the upper limit of normal.

Esperion's stock fluctuated throughout the day on the news, losing $7.93 (10%) to $70.01 in midday trading Wednesday, and ending the day off $1.65 to $76.29.

On the 269-patient trial's primary endpoint, once-daily 180 mg oral bempedoic acid as an add-on therapy led to a...

Read the full 500 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >